Sohini Das

All stories by Sohini Das

Raymond forays into real estate with Thane project

Raymond forays into real estate with Thane project

Rediff.com4 Apr 2019

The project will house 3,000 residential units across 10 towers in the first phase on a 20-acre land parcel that Raymond owns in Thane

Why cold wave across US is good news for Indian drug cos

Why cold wave across US is good news for Indian drug cos

Rediff.com12 Mar 2019

Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit.

Jio likely to grab 51% revenue market share in 3 years

Jio likely to grab 51% revenue market share in 3 years

Rediff.com7 Jan 2019

Airtel and Vodafone Idea are also trying to expand the penetration of 4G users in their subscriber base as they take this network to the hinterland

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

Rediff.com6 Dec 2018

Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Rediff.com9 Nov 2018

Singh, who was instrumental in building required capabilities in the organisation said his role at Fortis did not allow him to spend time with his family, as the reason behind his resignation.

J&J's loss may be good news for Indian pharmas

J&J's loss may be good news for Indian pharmas

Rediff.com1 Nov 2018

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

Why drug firms' Q2 revenue growth is likely to dip

Why drug firms' Q2 revenue growth is likely to dip

Rediff.com12 Oct 2018

Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.

Quality perceptions hobble Jan Aushadi drugs

Quality perceptions hobble Jan Aushadi drugs

Rediff.com10 Oct 2018

Large pharmaceutical firms feel that if the quality parameters and assurance levels are brought up to the level of branded generics, then Jan Aushadhi medicines would find it difficult to retain their affordability.

Why draft pharma policy may take time to see light of day

Why draft pharma policy may take time to see light of day

Rediff.com25 Sep 2018

Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.

How Amul is quelling the 'non-veg' rumours

How Amul is quelling the 'non-veg' rumours

Rediff.com21 Sep 2018

This is not the first time Gujarat Cooperative Milk Marketing Federation that owns brand Amul has chosen an unconventional method to protect its brand.

Faulty hip implants: Centre to ask J&J to compensate victims

Faulty hip implants: Centre to ask J&J to compensate victims

Rediff.com30 Aug 2018

Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement.

How Manipal plans to spread its wings in India

How Manipal plans to spread its wings in India

Rediff.com16 Aug 2018

Rough estimates show that at a rate of Rs 1 crore per hospital bed, the investment in India alone would be around Rs 2,000 crore

Pharma industry bounces back to good health

Pharma industry bounces back to good health

Rediff.com12 Jun 2018

In May, price growth for drugs was in negative territory at (-)1 per cent

Why Modi's dream of starting bullet train by 2022 may be derailed

Why Modi's dream of starting bullet train by 2022 may be derailed

Rediff.com21 May 2018

While farmers in Gujarat are rejecting the compensation package, farmers in Maharashtra say they do not wish to part with their land for a project that largely benefits Gujarat.

Takeover battle over, Munjal-Burman team bags Fortis

Takeover battle over, Munjal-Burman team bags Fortis

Rediff.com11 May 2018

Their offer values Fortis at over Rs 9,000 crore, or around Rs 172 per share.

Prices of key diabetes, cancer drugs may drop by 25%

Prices of key diabetes, cancer drugs may drop by 25%

Rediff.com8 Mar 2018

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.

Scooter sales get a major boost from rural India

Scooter sales get a major boost from rural India

Rediff.com23 Jan 2018

In first 9 months of FY18, scooter sales grew by 18.5%, the number may jump further as more women join workforce

In a first, a robot will perform angioplasty in Ahmedabad hospital

In a first, a robot will perform angioplasty in Ahmedabad hospital

Rediff.com5 Jan 2018

The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.

Battle hots up between Triumph Motorcycles and Royal Enfield

Battle hots up between Triumph Motorcycles and Royal Enfield

Rediff.com1 Jan 2018

Triumph's portfolio includes high-powered bikes such as the Daytona 200, Rocket III, SuperSports Daytona 675R and Tiger 800, apart from its iconic Bonneville family.

Jignesh Mevani is busy fighting the good fight

Jignesh Mevani is busy fighting the good fight

Rediff.com1 Jan 2018

'I fight for anyone who is poor, marginalised or victimised.' 'If a Dalit factory owner is inflicting atrocities on his Brahmin worker, then I will fight for the poor Brahmin.'

Prev  |  Next